Appointment of Nominated Adviser and Broker
01 February 2012
Instem plc
("Instem", the "Company" or the "Group")
Appointment of Nominated Adviser and Broker
Instem plc (the "Company") announces that, as a result of the completion of the transfer of the business of the Corporate Advisory & Broking division of Brewin Dolphin Limited to Nplus1 Brewin LLP ("N+1 Brewin"), with effect from today, N+1 Brewin has been appointed as the Company's Nominated Adviser and Broker.
For further information, please contact:
Instem plc | www.instem.com |
Phil Reason, CEO | +44 (0) 1785 825600 |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Richard Lindley | |
Nick Owen | |
James White | |
Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
Paul Cornelius | or instem@walbrookpr.com |
Sam Allen | |
Helen Cresswell | |
Paul Whittington |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.